Search tips
Search criteria 


Logo of wtpaEurope PMCEurope PMC Funders GroupSubmit a Manuscript
J Infect Dis. Author manuscript; available in PMC 2009 September 11.
Published in final edited form as:
PMCID: PMC2742199

Tumor Necrosis Factor and Lymphotoxin-α Polymorphisms and Severe Malaria in African Populations


The tumor necrosis factor gene (TNF) and lymphotoxin-α gene (LTA) have long attracted attention as candidate genes for susceptibility traits for malaria, and several of their polymorphisms have been found to be associated with severe malaria (SM) phenotypes. In a large study involving > 10,000 individuals and encompassing 3 African populations, we found evidence to support the reported associations between the TNF −238 polymorphism and SM in The Gambia. However, no TNF/LTA polymorphisms were found to be associated with SM in cohorts in Kenya and Malawi. It has been suggested that the causal polymorphisms regulating the TNF and LTA responses may be located some distance from the genes. Therefore, more-detailed mapping of variants across TNF/LTA genes and their flanking regions in the Gambian and allied populations may need to be undertaken to find any causal polymorphisms.

Malaria is a complex disease with many genetic and environmental determinants influencing the observed variation in the response to infection and the progression and severity of infection. To develop effective vaccines and antimalarial therapies, which are needed to control the serious toll of malaria-associated morbidity and mortality, it is crucial to understand the mechanisms of protective immunity against malaria, as well as the immunopathology of the disease. Cytokines are critical to the functioning of both innate and adaptive immune responses, and they are key regulators of the host response to infection. Identification of the polymorphisms regulating the cytokine response will assist in understanding the variation in response to infection.

Tumor necrosis factor (TNF) and lymphotoxin-α(LTA) have long attracted attention as candidate genes for susceptibility traits for malaria. TNF-α was the first cytokine shown to be present in elevated levels in humans with severe malaria (SM) [1, 2], and polymorphisms of the promoter region of the TNF gene have been extensively investigated [3, 4]. The TNF −376 polymorphism acts to modulate transcription factor Oct-1 in human monocytes in vitro, and it is associated with susceptibility to SM [4]. In particular, in a Gambian population, carriers of the TNF −376A allele were found to be at an increased risk for cerebral malaria (CM), and this observation was confirmed in a study performed in Kenya [4]. Additional variants TNF −308 and TNF −238 have been found to be associated with clinical subphenotypes of malaria. Gambian children who are homozygous for the TNF −308A allele also have an increased susceptibility to CM [3] but not to severe malarial anemia (SMA). Further research in the same population suggested that the TNF −238A allele is associated with SMA, leading to speculation that SMA and CM are associated with different TNF promoter alleles (TNF −238 and TNF −308) [5]. The results from additional studies (some of which were underpowered) in other populations have not been consistent (table 1). The functional significance of TNF −238 and TNF −308 is controversial, because some evidence is derived from underpowered studies and could be confounded by haplotypic heterogeneity (for a summary of the functional evidence, see [16, 17]).

Table 1
Studies of malaria and lymphotoxin-α(LTA) and tumor necrosis factor (TNF) genes.

TNF and LTA are neighboring genes that are in high linkage disequilibrium (LD) with each other [18]. In particular, TNF −308 forms an extended haplotype with polymorphisms in LTA. Genetic variation in the LTA locus in humans has been found to be associated with susceptibility to myocardial infarction [19], bacterial infection [20], asthma [21], leprosy [22], and other diseases [23]. It has also been shown that LTA is a principal mediator of murine CM [24]. The common LTA haplotype is defined uniquely by 2 markers, one of which, the LTA +80 polymorphism, shows evidence of allele-specific binding by a transcriptional repressor, ABF-1 [17]. There is also some evidence that the other marker, the LTA +252 polymorphism, modulates reporter gene expression and, possibly, protein-DNA binding [17].

In the present study, we investigated whether a number of LTA and TNF single-nucleotide polymorphisms (SNPs), including the functional LTA +80 polymorphism and the potentially functional TNF −376, −308, and −238 polymorphisms, are associated with SM. This investigation considered multiple African populations (in The Gambia, Kenya and Malawi) by using both family- and population-based studies. We sought to clarify the previous association discrepancies in the TNF/LTA region by using the largest sample collections of SM available to date.


Sample preparation and genotyping

Genomic DNA samples underwent whole-genome amplification through either primer extension preamplification [25] or multiple displacement amplification [26], before genotyping was done on a Sequenom MassArray genotyping platform [27, 28]. The following SNPs were genotyped: (1) hemoglobin variant S (HbS) (rs334), (2) LTA +252 (T252C; rs909253), (3) LTA +80 (G80T; rs2239704), (4) TNF +851 (A851G; rs3093662), (5) TNF −238 (G238A; rs361525), (6) TNF −308 (G308A; rs1800629), (7) TNF −376 (G376A; rs1800750), and (8) TNF −1031 (T1031C; rs1799964). TNF and LTA SNP selection was based on haplotype tags [29] and a previous association with malaria. Figure 1 shows a genetic map for the ~4-kb region in which the LTA/TNF polymorphisms that are being considered reside. All TNF polymorphisms are located within the promoter region, except TNF +851, which is located in the exonic region of the gene. The HbS polymorphism is used to calibrate our results, because it is known to be under heterozygous advantage for SM.

Figure 1
The lymphotoxin-α gene (LTA) and tumor necrosis factor gene (TNF) region and the polymorphisms genotyped.

Study participants

Patient samples were collected as part of ongoing epidemiologic studies of SM at the Royal Victoria Hospital in Banjul, The Gambia (2491 case patients with SM, 3881 cord blood controls, and 1055 family trios); Kilifi District Hospital in Kilifi, Kenya (927 case patients with SM and 953 cord blood controls); and the Queen Elizabeth Central Hospital in Blantyre, Malawi (1629 case patients with SM and 3578 cord blood controls). The set of nuclear family trios comprise a child affected with SM and its 2 (biological) parents, and they were assessed as “true trios” by use of the Nucl3ar software package (version 1.0) [30]. All DNA samples were collected and genotyped after approval was provided by the relevant research ethics committees and written informed consent was provided by the participants.

Phenotypic definition

All cases were children admitted to the hospital with evidence of Plasmodium falciparum on blood film and clinical characteristics of SM [31, 32]. Subjects were defined as having had CM if their Blantyre coma score was [less-than-or-eq, slant]2 at presentation or early during admission. A second phenotypic subset of individuals with SMA was defined as those subjects who had a hemoglobin concentration of <5 g/dL or a hematocrit of <15%. Participants with coexisting severe or chronic medical conditions (e.g., bacterial pneumonia or kwashiorkor) unrelated to a SM were excluded. The ratio of case patients with CM to case patients with SMA was ~2.30, 0.95, and 3.38 to 1 in the Gambian, Kenyan, and Malawian populations, respectively. Control samples were cord blood samples obtained from birth clinics in the same hospital as the case patient samples, and they were thus thought to approximate a random sample of the population, reflecting the true population allele frequency.

Statistical analysis

Genotypic deviations from Hardy-Weinberg equilibrium (HWE) were assessed using a χ2 statistical test. Case-control association analysis using SNP alleles/geno-types and haplotypes was undertaken by logistic regression and included the following covariates: ethnic group and HbS polymorphism. Haplotypes were estimated using an expectation-maximization algorithm [33], and score tests [34] were applied to assess the level of evidence of both global and individual haplotype associations with malaria. Family-based association analysis was performed on SNPs and haplotypes by use of the transmission disequilibrium test (TDT) [35]. All analyses were performed using the R statistical package [36].


Figure 1 shows the LTA and TNF polymorphisms considered in the Gambian, Kenyan, and Malawian populations. The minor allele frequencies for the HbS, LTA, and TNF polymorphisms are presented in table 2. Only the genotypes for the TNF −1031 and TNF −376 polymorphisms in the Gambian and Malawian controls, respectively, show any evidence of distortion from Hardy-Weinberg equilibrium (P < .001). Most heterogeneity in allele frequencies appears in the LTA +80T, LTA +252C, and TNF −1031C alleles, where there are differences between the Gambian and non-Gambian populations. Table 3 shows the results of the tests of allelic association. The HbS S allele has a significant protective effect on SM across all studies (P < 10−8). An analysis of HbS genotypes confirmed the protective effect of the heterozygous state with a ~90% reduced risk of SM across all populations. In particular, in The Gambia, Kenya, and Malawi, the odds ratios (ORs) for the AS vs. AA/SS genotypes are 0.09 (95% confidence interval [CI], 0.06–0.13; P < .001), 0.16 (95% CI, 0.10–0.27; P < .001), and 0.11 (95% CI, 0.06–0.22; P < .001), respectively. These results were consistent when considering CM and SMA cases separately.

Table 2
Minor allele frequencies.
Table 3
Allelic tests of association with severe malaria in case-control studies.

The allelic test for the LTA +252C polymorphism in the Malawian population suggested a marginal protective effect. A genotype analysis (for LTA +252, CC/CT vs. TT) in this population confirmed the marginal protective effect (OR, 0.86; 95% CI, 0.76–0.99; P = .038). There was a similar genotypic effect (for LTA +252, CC vs. TC/TT) in the Gambian population (OR, 0.87; 95% CI, 0.75–1.02), but it did not reach statistical significance (P = .080). There is some evidence to suggest that the TNF −238A allele increases the risk of SM in both the Gambian case-controls (P = .061) and the trios (P = .028) but not in other populations. Genotype analysis (AA/GA vs. GG) in the Gambian case-control study suggested an increase in the risk of SM (OR, 1.21; 95% CI, 1.04–1.42; P = .016). This result was consistent across populations with CM (OR, 1.21; 95% CI, 1.04–1.42; P = .016) and SMA (OR, 1.29; 95% CI, 1.01–1.65; P = .042). From the trio analysis, there is some evidence that the TNF −376A allele leads to disease susceptibility (OR, 1.85; 95% CI, 1.07–3.19; P = .027). However, these results were not replicated in the Gambian case-control study (P = .853), and, in the present study, there was no evidence of genotypic effects (AA/GA vs. GG) across all individuals with SM (OR, 1.05; 95% CI, 0.81−1.38; P = .704) and clinical subphenotypes (for CM, P = .626; for SMA, P = .997). In the Gambian case-control study, allelic-based tests of the TNF −308 polymorphism indicated possible disease susceptibility in association with the A allele (P = .032). This result was not confirmed in the genotype analysis (AA/GA vs. GG) of all individuals with severe disease (OR, 1.10; 95% CI, 0.98–1.23; P = .123) and clinical subphenotypes (for CM, P = .207; for SMA, P = .442).

The pairwise linkage disequilibrium (LD) patterns (using D′ and r2 metrics) for the population controls are presented in figure 2. There is a high degree of LD within populations, and its patchy nature is consistent with previous reports [25]. There are differences in the patterns between populations—for example, the LD between LTA polymorphisms is higher in Malawian controls, but, between LTA and TNF polymorphisms, it is comparatively lower in the same population. On the basis of the Gambian results in table 4, we performed a haplotype analysis of the TNF region (TNF +851, TNF −238, TNF −308, and TNF −376) in this population, and we found that there was some evidence of global association (P < .002). In particular, compared with the common AGGG haplotype, both AGAG and GAGG are associated with a 10%–30% increased risk of SM (P < .03). Similar haplotype analyses failed to find strong associations in the Kenyan (P = .301) and Malawian (P = .410) populations (table 3). Analysis of the Gambian trios suggested that the common AGGG haplotype was associated with a reduction in the risk of SM (relative risk [RR], 0.88; 95% CI, 0.77–1.00), whereas the GAGG haplotype was associated with an increase in risk (RR, 1.32; 95% CI, 1.01–1.74) (results not shown). In addition, there was no strong evidence of global association in LTA (LTA +80 and LTA +252) haplotypes and SM (for The Gambia, P = .295; for Kenya, P = .207; and for Malawi, P = .134) (results not shown).

Figure 2
Pairwise linkage disequilibrium (D′ and r2) in the population controls
Table 4
Haplotype association analysis of tumor necrosis factor (TNF) polymorphisms and severe malaria in the case-control studies.


We conducted a genetic association study investigating the possible effect of candidate LTA and TNF polymorphisms and the HbS polymorphism on SM in 3 African populations. The HbS polymorphism is under the strongest selective genetic pressures known in the human genome [37], and, as expected, there was a strong heterozygous protective effect on SM across all 3 populations. We found no consistent association signals for the TNF and LTA polymorphisms across all 3 populations. This result coincides with the interstudy discrepancies found in previously reported association studies of the candidate TNF and LTA polymorphisms (table 1). These apparent discrepancies may be the result of a number of study characteristics, including: (1) the differences in sample size and the resulting statistical power, (2) phenotypic differences, (3) haplotypic diversity between populations and the effects of population structure, and (4) differences in study design (e.g., village surveys or hospital-based studies). In the present study, we considered some of the largest sample sets collected to date and a standardized protocol with a definition of SM. In addition, we used only cord blood controls and attempted to adjust for the potential effects of population structure by adjusting for ethnicity and location in case-control studies, as well as by using the robust study design including affected child–parent trios.

The TNF and LTA genes have been implicated in the host defense and pathogenesis of SM (reviewed in [38, 39]). Our analyses reveal that there is some evidence that TNF haplotypes (constructed from the SNPs considered) are associated with SM in the Gambian population but not in the closely related populations of Kenya and Malawi. This result may be explained by the occurrence of a selective event in the Gambian population that has not spread to or arisen in East Africa; the effect of such a variant is being detected because it is in LD with the TNF/LTA polymorphisms. Indeed, it has been suggested that the causal polymorphisms regulating the TNF and LTA response may be located some distance downstream of the genes [29, 40].

Furthermore, African populations have a high degree of diversity, and there may be allelic heterogeneity in the TNF/LTA region. Therefore, it is possible that the polymorphisms considered in the present study are not in sufficiently strong LD with any actual causal variants in Kenya and Malawi. Similar inter-population haplotype heterogeneity has been demonstrated in the G6PD region [41], and there is strong evidence to suggest that the sickle trait arose on different haplotype backgrounds [37]. If the same effects are present for TNF/LTA, it would decrease the power of a study and could account for the inability to detect a clear signal of association in our study and others. This issue of malaria disease association mapping on the background of African genetic variation remains the main challenge facing this field of study. Further dense mapping in the major histo-compatibility complex (MHC) class III region in the Gambian and allied populations may be necessary to identify any functional variants of TNF and LTA for SM.


We thank the patients from the Gambian, Kenyan, and Malawian malaria study populations, as well as the many investigators involved in the original studies in these populations, for their contributions.

Financial support: The Bill and Melinda Gates Foundation; Wellcome Trust; Medical Research Council United Kingdom; Fundação para a Ciência e Tecnologia, Ministério da Ciência e Tecnologia (Portuguese Post-Doc fellowship to S.C.); Wellcome Trust Clinical Research Training Fellowship (to A.E.F.); Wellcome Trust, MalariaGEN, and European Union Network 6 BioMalPar Consortium (funding to T.N.W.); International Atomic Energy Agency (training fellowship to M.D.).


Potential conflicts of interest: none reported.


1. Kwiatkowski D, Hill AV, Sambou I, et al. TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet. 1990;336:1201–4. [PubMed]
2. Grau GE, Taylor TE, Molyneux ME, et al. Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med. 1989;320:1586–91. [PubMed]
3. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature. 1994;371:508–10. [PubMed]
4. Knight JC, Udalova I, Hill AV, et al. A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nat Genet. 1999;22:145–50. [PubMed]
5. McGuire W, Knight JC, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. J Infect Dis. 1999;179:287–90. [PubMed]
6. Wattavidanage J, Carter R, Perera KL, et al. TNFα*2 marks high risk of severe disease during Plasmodium falciparum malaria and other infections in Sri Lankans. Clin Exp Immunol. 1999;115:350–5. [PubMed]
7. Flori L, Delahaye NF, Iraqi FA, Hernandez-Valladares M, Fumoux F, Rihet P. TNF as a malaria candidate gene: polymorphism-screening and family-based association analysis of mild malaria attack and parasitemia in Burkina Faso. Genes Immun. 2005;6:472–80. [PubMed]
8. Migot-Nabias F, Mombo LE, Luty AJ, et al. Human genetic factors related to susceptibility to mild malaria in Gabon. Genes Immun. 2000;1:435–41. [PubMed]
9. Mombo LE, Ntoumi F, Bisseye C, et al. Human genetic polymorphisms and asymptomatic Plasmodium falciparum malaria in Gabonese school-children. Am J Trop Med Hyg. 2003;68:186–90. [PubMed]
10. Cabantous S, Doumbo O, Ranque S, et al. Alleles 308A and 238A in the tumor necrosis factor alpha gene promoter do not increase the risk of severe malaria in children with Plasmodium falciparum infection in Mali. Infect Immun. 2006;74:7040–2. [PMC free article] [PubMed]
11. Stirnadel HA, Stöckle M, Felger I, Smith T, Tanner M, Beck HP. Malaria infection and morbidity in infants in relation to genetic polymorphisms in Tanzania. Trop Med Int Health. 1999;4:187–93. [PubMed]
12. Parikh S, Dorsey G, Rosenthal PJ. Host polymorphisms and the incidence of malaria in Ugandan children. Am J Trop Med Hyg. 2004;71:750–3. [PubMed]
13. Aidoo M, McElroy PD, Kolczak MS, et al. Tumor necrosis factor-α promoter variant 2 (TNF2) is associated with pre-term delivery, infant mortality, and malaria morbidity in western Kenya: Asembo Bay Cohort Project IX. Genet Epidemiol. 2001;21:201–11. [PubMed]
14. Hananantachai H, Patarapotikul J, Looareesuwan S, Ohashi J, Naka I, Tokunaga K. Lack of association of −308A/G TNFA promoter and 196R/M TNFR2 polymorphisms with disease severity in Thai adult malaria patients. Am J Med Genet. 2001;102:391–2. [PubMed]
15. Hananantachai H, Patarapotikul J, Ohashi J, et al. Significant association between TNF-alpha (TNF) promoter allele (−1031C, −863C, and −857C) and cerebral malaria in Thailand. Tissue Antigens. 2007;69:277–80. [PubMed]
16. Bayley JP, Ottenhoff TH, Verweij CL. Is there a future for TNF promoter polymorphisms? Genes Immun. 2004;5:315–29. [PubMed]
17. Knight JC, Keating BJ, Kwiatkowski DP. Allele-specific repression of lymphotoxin-α by activated B cell factor-1. Nat Genet. 2004;36:394–9. [PubMed]
18. Stenzel A, Lu T, Koch WA, et al. Patterns of linkage disequilibrium in the MHC region on human chromosome 6p. Hum Genet. 2004;114:377–85. [PubMed]
19. Clarke R, Xu P, Bennett D, et al. Lymphotoxin-α gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study. PLoS Genet. 2006;2:e107. [PubMed]
20. Roach DR, Briscoe H, Saunders B, France MP, Riminton S, Britton WJ. Secreted lymphotoxin-α is essential for the control of an intracellular bacterial infection. J Exp Med. 2001;193:239–46. [PMC free article] [PubMed]
21. Migita O, Noguchi E, Koga M, et al. Haplotype analysis of a 100 kb region spanning TNF-LTA identifies a polymorphism in the LTA promoter region that is associated with atopic asthma susceptibility in Japan. Clin Exp Allergy. 2005;35:790–6. [PubMed]
22. Alcais A, Alter A, Antoni G, et al. Stepwise replication identifies a low-producing lymphotoxin-α allele as a major risk factor for early-onset leprosy. Nat Genet. 2007;39:517–22. [PubMed]
23. Knight JC. Regulatory polymorphisms underlying complex disease traits. J Mol Med. 2005;83:97–109. [PMC free article] [PubMed]
24. Engwerda CR, Mynott TL, Sawhney S, De Souza JB, Bickle QD, Kaye PM. Locally up-regulated lymphotoxin α, not systemic tumor necrosis factor α, is the principle mediator of murine cerebral malaria. J Exp Med. 2002;195:1371–7. [PMC free article] [PubMed]
25. Zhang L, Cui X, Schmitt K, Hubert R, Navidi W, Arnheim N. Whole genome amplification from a single cell: implications for genetic analysis. Proc Natl Acad Sci USA. 1992;89:5847–51. [PubMed]
26. Gonzalez JM, Portillo MC, Saiz-Jimenez C. Multiple displacement amplification as a pre-polymerase chain reaction (pre-PCR) to process difficult to amplify samples and low copy number sequences from natural environments. Environ Microbiol. 2005;7:1024–8. [PubMed]
27. Ross P, Hall L, Smirnov I, Haff L. High level multiplex genotyping by MALDI-TOF mass spectrometry. Nat Biotechnol. 1998;16:1347–51. [PubMed]
28. Wilson JN, Rockett K, Jallow M, et al. Analysis of IL10 haplotypic associations with severe malaria. Genes Immun. 2005;6:462–6. [PubMed]
29. Ackerman HC, Ribas G, Jallow M, et al. Complex haplotypic structure of the central MHC region flanking TNF in a West African population. Genes Immun. 2003;4:476–86. [PubMed]
30. Teo YY, Fry AE, Sanjoaquin MA, et al. Assessing parents-offspring trios for genetic association studies. Hum Hered. 2009;67:26–37. [PMC free article] [PubMed]
31. Marsh K, Forster D, Waruiru C, et al. Indicators of life-threatening malaria in African children. N Engl J Med. 1995;332:1399–404. [PubMed]
32. Division of Control of Tropical Diseases. World Health Organization Severe and complicated malaria. Trans R Soc Trop Med Hyg. 1990;84(Suppl 2):1–65. [PubMed]
33. Lake SL, Lyon H, Tantisira K, et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered. 2003;55:56–65. [PubMed]
34. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002;70:425–34. [PubMed]
35. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM) Am J Hum Genet. 1993;52:506–16. [PubMed]
36. The R project for statistical computing. Available at: Accessed 25 November 2008. [PubMed]
37. Kwiatkowski DP. How malaria has affected the human genome and what human genetics can teach us about malaria. Am J Hum Genet. 2005;77:171–92. [PubMed]
38. Clark IA, Alleva LM, Mills AC, Cowden WB. Pathogenesis of malaria and clinically similar conditions. Clin Microbiol Rev. 2004;17:509–39. table of contents. [PMC free article] [PubMed]
39. Campino S, Kwiatkowski D, Dessein A. Mendelian and complex genetics of susceptibility and resistance to parasitic infections. Semin Immunol. 2006;18:411–22. [PubMed]
40. Newton JL, Harney SM, Timms AE, et al. Dissection of class III major histocompatibility complex haplotypes associated with rheumatoid arthritis. Arthritis Rheum. 2004;50:2122–9. [PubMed]
41. Clark TG, Fry AE, Auburn S, et al. Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility. Eur J Hum Genet. in press. [PMC free article] [PubMed]